Fifty-four novel mutations in the NF1 gene and integrated analyses of the mutations that modulate splicing

Xu,Weihong; Yang,Xiao; Hu,Xiaoxia; Li,Shibo

doi:10.3892/ijmm.2014.1756

Fifty-four novel mutations in the NF1 gene and integrated analyses of the mutations that modulate splicing

Authors:
- Weihong Xu
- Xiao Yang
- Xiaoxia Hu
- Shibo Li
View Affiliations

Affiliations: Genetics Laboratory, Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA
Published online on: April 24, 2014 https://doi.org/10.3892/ijmm.2014.1756
Pages: 53-60
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder caused by mutations in the NF1 gene. One of the hallmarks of NF1 is the high mutation rate in this gene. In this study, we present 127 different NF1 mutations and 54 novel mutations detected at both the genomic DNA and mRNA level using a retrospective case series review. We found that 25.2% of these different mutations induced aberrant splicing. Of note, 40.6% of these splicing errors were caused by exonic variants. In addition, one mutation produced mosaicism in the post-transcriptional profile. However, studies investigating these splicing aberrations are limited. In order to better understand the pathogenicity of NF1 and to provide a more accurate interpretation in molecular diagnostic testing, combined computational analyses were employed to elucidate the underlying mechanisms of the variants modulating NF1 gene splicing.

View Figures

View References

1	Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B and Maria BL: Neurofibromatosis type 1 revisited. Pediatrics. 123:124–133. 2009. View Article : Google Scholar : PubMed/NCBI
2	No authors listed. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 45:575–578. 1988.PubMed/NCBI
3	Griffiths S, Thompson P, Frayling I and Upadhyaya M: Molecular diagnosis of neurofibromatosis type 1: 2 years experience. Fam Cancer. 6:21–34. 2007.PubMed/NCBI
4	Pasmant E, Sabbagh A, Spurlock G, Laurendeau I, Grillo E, Hamel MJ, Martin L, Barbarot S, Leheup B, Rodriguez D, Lacombe D, Dollfus H, Pasquier L, Isidor B, Ferkal S, Soulier J, Sanson M, Dieux-Coeslier A, Bièche I, Parfait B, Vidaud M, Wolkenstein P, Upadhyaya M and Vidaud D; members of the NF France Network. NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat. 31:1506–1518. 2010. View Article : Google Scholar : PubMed/NCBI
5	Aoki Y, Niihori T, Narumi Y, Kure S and Matsubara Y: The RAS/MAPK Syndromes: Novel roles of the RAS pathway in human genetic disorders. Hum Mutat. 29:992–1006. 2008. View Article : Google Scholar : PubMed/NCBI
6	Cichowski K and Jacks T: NF1 tumor suppressor gene function: narrowing the GAP. Cell. 104:593–604. 2001. View Article : Google Scholar : PubMed/NCBI
7	Yunoue S, Tokuo H, Fukunaga K, Feng L, Ozawa T, Nishi T, Kikuchi A, Hattori S, Kuratsu J, Saya H and Araki N: Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras. J Biol Chem. 278:26958–26969. 2003. View Article : Google Scholar
8	Schubbert S, Shannon K and Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 7:295–308. 2007. View Article : Google Scholar : PubMed/NCBI
9	Trovó-Marqui AB and Tajara EH: Neurofibromin: a general outlook. Clin Genet. 70:1–13. 2006.
10	Nemethova M, Bolcekova A, Ilencikova D, Durovcikova D, Hlinkova K, Hlavata A, Kovacs L, Kadasi L and Zatkova A: Thirty-nine novel neurofibromatosis 1 (NF1) gene mutations identified in Slovak patients. Ann Hum Genet. 77:364–379. 2013.PubMed/NCBI
11	Ko JM, Sohn YB, Jeong SY, Kim HJ and Messiaen LM: Mutation spectrum of NF1 and clinical characteristics in 78 Korean patients with neurofibromatosis type 1. Pediatr Neurol. 48:447–453. 2013. View Article : Google Scholar : PubMed/NCBI
12	Zhang C, Li WH, Krainer AR and Zhang MQ: RNA landscape of evolution for optimal exon and intron discrimination. Proc Natl Acad Sci USA. 105:5797–5802. 2008. View Article : Google Scholar : PubMed/NCBI
13	Kolovos P, Knoch TA, Grosveld FG, Cook PR and Papantonis A: Enhancers and silencers: an integrated and simple model for their function. Epigenetics Chromatin. 5:12012. View Article : Google Scholar : PubMed/NCBI
14	Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, Speleman F and Paepe AD: Exhaustive mutation analysis of the NF1gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat. 15:541–555. 2000.PubMed/NCBI
15	Ars E, Serra E, Garcia J, Kruyer H, Gaona A, Lázaro C and Estivill X: Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Hum Mol Genet. 9:237–247. 2000. View Article : Google Scholar : PubMed/NCBI
16	Zatkova A, Messiaen L, Vandenbroucke I, Wieser R, Fonatsch C, Krainer AR and Wimmer K: Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1. Hum Mutat. 24:491–501. 2004. View Article : Google Scholar : PubMed/NCBI
17	Wimmer K, Roca X, Beiglböck H, Callens T, Etzler J, Rao A, Krainer A, Fonatsch C and Messiaen L: Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5′ splice-site disruption. Hum Mutat. 28:599–612. 2007.PubMed/NCBI
18	Pros E, Gómez C, Martín T, Fábregas P, Serra E and Lázaro C: Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations. Hum Mutat. 29:E173–E193. 2008. View Article : Google Scholar : PubMed/NCBI
19	Sironi M, Menozzi G, Riva L, Cagliani R, Comi GP, Bresolin N, Giorda R and Pozzoli U: Silencer elements as possible inhibitors of pseudoexon splicing. Nucleic Acids Res. 32:1783–1791. 2004. View Article : Google Scholar : PubMed/NCBI
20	Ars E, Kruyer H, Morell M, Pros E, Serra E, Ravella A, Estivill X and Lázaro C: Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients. J Med Genet. 40:e822003. View Article : Google Scholar : PubMed/NCBI
21	Castle B, Baser ME, Huson SM, Cooper DN and Upadhyaya M: Evaluation of genotype-phenotype correlations in neurofibromatosis type 1. J Med Genet. 40:e1092003. View Article : Google Scholar : PubMed/NCBI
22	Kluwe L, Friedrich R, Korf B, Fahsold R and Mautner V: NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas. Hum Mutat. 19:3092002. View Article : Google Scholar : PubMed/NCBI
23	van Minkelen R, van Bever Y, Kromosoeto J, Withagen-Hermans C, Nieuwlaat A, Halley D and van den Ouweland A: A clinical and genetic overview of 18 years neurofibromatosis type 1 molecular diagnosis in the Netherlands. Clin Genet. May 18–2013.(Epub ahead of print).
24	Upadhyaya M, Huson SM, Davies M, Thomas N, Chuzhanova N, Giovannini S, Evans DG, Howard E, Kerr B, Griffiths S, Consoli C, Side L, Adams D, Pierpont M, Hachen R, Barnicoat A, Li H, Wallace P, Van Biervliet JP, Stevenson D, Viskochil D, Baralle D, Haan E, Riccardi V, Turnpenny P, Lazaro C and Messiaen L: An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970–2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am J Hum Genet. 80:140–151. 2007.PubMed/NCBI
25	Nelson KK and Green MR: Mechanism for cryptic splice site activation during pre-mRNA splicing. Proc Natl Acad Sci USA. 87:6253–6257. 1990. View Article : Google Scholar : PubMed/NCBI
26	Blencowe BJ: Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci. 25:106–110. 2000. View Article : Google Scholar : PubMed/NCBI
27	Colapietro P, Gervasini C, Natacci F, Rossi L, Riva P and Larizza L: NF1 exon 7 skipping and sequence alterations in exonic splice enhancers(ESEs) in a neurofibromatiosis 1 patient. Hum Genet. 113:551–554. 2003. View Article : Google Scholar : PubMed/NCBI
28	Vandenbroucke I, Callens T, De Paepe A and Messiaen L: Complex splicing pattern generates great diversity in human NF1 transcripts. BMC Genomics. 3:132002. View Article : Google Scholar : PubMed/NCBI
29	Wang Z, Rolish ME, Yeo G, Tung V, Mawson M and Burge CB: Systematic identification and analysis of exonic spicing silencers. Cell. 119:831–845. 2004. View Article : Google Scholar : PubMed/NCBI
30	Zhang XH and Chasin LA: Computational definition of sequence motifs governing constitutive exon splicing. Genes Dev. 18:1241–1250. 2004. View Article : Google Scholar : PubMed/NCBI
31	Baralle D and Baralle M: Splicing in action: assessing disease causing sequence changes. J Med Genet. 42:737–748. 2005. View Article : Google Scholar : PubMed/NCBI
32	Haque A, Buratti E and Baralle FE: Functional properties and evolutionary splicing constraints on a composite exonic regulatory element of splicing in CFTR exon 12. Nucleic Acids Res. 38:647–659. 2010. View Article : Google Scholar : PubMed/NCBI
33	Gottfried O, Viskochil D and Couldwell W: Neurofibromatosis type 1 and tumorigenesis: molecular mechanisms andtherapeutic implications. Neurosurg Focus. 28:E82010. View Article : Google Scholar : PubMed/NCBI